NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Vinflunine for the second line treatment of transitional cell carcinoma of the urothelial tract

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

Version of matrix of consultees and commentators reviewed:									
Provisional matrix of consultees and commentators sent for consultation									
Summary of comments, action taken, and justification of action:									
	Proposal:	Proposal made by:		Action taken: Removed/Added/Not included/Noted	Justification:				
1.	Remove Age Concern England from patient/carer group consultees.	NICE Secretariat		Removed	Completed as per the specific organisations request.				
2.	Remove British Ethnic Health Awareness Foundation (BEHAF) from patient/carer group consultees.	NICE Secretariat		Removed	British Ethnic Health Awareness Foundation (BEHAF) has been removed from the Charity Commission records and therefore doesn't meet the inclusion criteria.				

3.	Remove Confederation of Indian Organisations from patient/carer group consultees.	NICE Secretariat	Removed	Confederation of Indian Organisations have now closed, and therefore been removed from the matrix.
4.	Remove Help the Aged from patient/carer group consultees.	Help the Aged	Removed	Completed as per the specific organisations request.
5.	The British Urological-oncology Group (BUG) should be added as a professional group consultee.	Pierre Fabre	Added	The British Urological-oncology (BUG) meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a professional consultee.
6.	BOPA should be added as a professional group consultee.	Pierre Fabre	Not included	The Cancer Networks Pharmacist Forum is included on the matrix, BOPA are represented by this forum so do not need to be included separately.
7.	The Care Quality Commission (CQC) should be added as a general group commentator.	NICE Secretariat	Added	The Care Quality Commission (CQC) meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a general commentator.

Consultation comments on the matrix for technology appraisal of vinflunine for the second line treatment of transitional cell carcinoma of the urothelial tract Issue date: May 2010